triazoles has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 28 (65.12) | 24.3611 |
| 2020's | 15 (34.88) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, X; Wang, L; Wu, X; Xie, J; Xie, Y; Xu, H | 1 |
| Abdel-Salam, MAL; Barbosa, AS; Barcelos, LS; Cassali, GD; da Silva, AD; de Abreu Teles, PP; de Castro, QJT; de Lima, ME; de Souza, CP; de Souza-Fagundes, EM; Dos Reis, DC; Glanzmann, N; Grabe-Guimarães, A; Leite, EA; Nobre, DAB; Ramos, JP | 1 |
| Koestler, DC; Ly, T; Pei, D; Sardiu, ME; Thompson, JA; Welch, DR; Yellapu, NK | 1 |
| Agborbesong, E; Li, LX; Li, X; Zhou, JX | 1 |
| Cai, Z; Lai, H; Li, S; Li, Y; Liu, Y; Shi, Q; Wang, R | 1 |
| Burgos, M; Esparís-Ogando, A; Galán-Moya, EM; Gómez-Juárez, M; Montero, JC; Nieto-Jimenez, C; Noblejas-López, MDM; Ocaña, A; Pandiella, A | 1 |
| Andrieu, GP; Belkina, AC; Casey, AN; Denis, GV; Jafari, N; Shafran, JS; Smith, CL | 1 |
| Hwang, JA; Jeon, SY; Kim, MK; Kong, SY; Lee, KS; Park, IH; Shim, SH; Yang, HN | 1 |
| Anderhub, SJ; Blagg, J; Burke, R; Drosopoulos, K; Eccles, SA; Faisal, A; Filosto, S; Gurden, MD; Hayes, A; Hoelder, S; Innocenti, P; Linardopoulos, S; Mak, GW; Naud, S; Raynaud, FI; Saville, H; Theofani, E; van Montfort, RLM; Walsh, K; Westwood, IM; Woodward, HL | 1 |
| Liao, X; Lu, G; Tian, Y; Wang, S; Wang, X; Younis, MR; Zhang, C; Zhao, S | 1 |
| Chandler, B; Eisner, J; Feng, FY; Hayes, D; Liu, M; Michmerhuizen, AR; Moubadder, L; Nyati, S; Olsen, E; Pesch, AM; Pierce, LJ; Rae, JM; Ritter, C; Santola, A; Speers, C; Spratt, D; Wahl, D; Ward, ST; Wilder-Romans, K; Zhang, A | 1 |
| Burgos, M; Corrales-Sanchez, V; Galán-Moya, EM; Győrffy, B; Morcillo-Garcia, S; Nieto-Jimenez, C; Nuncia-Cantarero, M; Ocaña, A; Perez-Peña, J; Serrano-Oviedo, L | 1 |
| Boyce, BF; Duan, R; Huston, A; Lei, W; Li, J; Liu, X; Yao, Z | 1 |
| Gu, S; Jing, X; Luo, A; Shao, S; Zhang, L; Zhang, Y; Zhao, L; Zhao, X | 1 |
| Brown, M; Fassl, A; Ge, JY; Gulvady, A; Heavey, GA; Jovanović, B; Kuang, Y; Kwon, M; Luoma, A; McDonald, TO; Michor, F; Murphy, K; Paweletz, C; Pellman, D; Polyak, K; Qi, J; Shu, S; Sicinski, P; Thorner, AR; Trinh, A; Wucherpfennig, KW | 1 |
| Anand, J; Bradner, J; Brown, M; Brugge, JS; Carroll, JS; Cejas, P; D'Santos, C; Endress, JE; Font-Tello, A; Ge, JY; Harris, IS; Hinohara, K; Jaffe, JD; Jovanović, B; Kadoch, C; Li, W; Lim, K; Liu, XS; Long, H; Luoma, A; McDonald, TO; Michel, B; Michor, F; Modiste, RJ; Murphy, K; Nguyen, QD; Papachristou, EK; Polyak, K; Qi, J; Qiu, X; Reddy Chilamakuri, CS; Reyes, J; Shu, S; Syamala, S; Wang, B; Wu, HJ; Wucherpfennig, KW; Xiao, T; Zeid, R | 1 |
| Chen, M; Lv, L; Quan, D; Schmitz, JC; Tian, N; Tian, Y; Wei, N; Wu, H; Wu, S; Xie, Y; Xu, Y; Yang, D; Yang, Z; Zhang, H; Zhang, J; Zhang, T; Zhou, L | 1 |
| Burgos, M; Corrales-Sanchez, V; Domingo, B; Esparis-Ogando, A; Galan-Moya, EM; Gomez-Juarez, M; Montero, JC; Nieto-Jimenez, C; Noblejas-Lopez, MDM; Ocaña, A; Pandiella, A; Picazo-Martinez, MG | 1 |
| Chen, L; Craven, R; Hamad, N; He, S; Huang, JA; Li, J; Liu, C; Liu, Z; Lu, X; Napier, D; Pan, Y; Qian, H; Shi, J; Thibault, O; Wang, C; Wei, D; Wei, X; Wu, Y; Xu, B; Xu, L; Yang, H; Yang, XH; Zhang, Y; Zheng, X; Zhou, BP | 1 |
| Argueta, C; Croce, A; Daidone, MG; De Marco, C; Figini, M; Frigerio, B; Gianni, AM; Landesman, Y; Martini, S; Pennati, M; Satta, A; Zaffaroni, N | 1 |
| Alves, D; Begnini, KR; Buss, JH; Collares, T; da Silva, LP; Duarte, WR; Fronza, M; Goldani, BS; Savegnago, L; Segatto, NV; Seixas, FK | 1 |
| Akcakanat, A; Arango, NP; Evans, KW; Gonzalez-Angulo, AM; Janku, F; Kim, C; Meric-Bernstam, F; Naing, A; Scott, S; Tripathy, D; Ueno, NT; Yuca, E; Zhao, M | 1 |
| Büsselberg, D; Fawaz, F; Shah, S; Shaheen, S | 1 |
| Adey, A; Alvarez, MJ; Aswani, AJ; Boniface, C; Califano, A; Chapman, MP; Chin, K; Dobrolecki, LE; Fields, AJ; Gray, JW; Johnson-Camacho, K; Kendsersky, ND; Langer, EM; Lewis, MT; Pelz, CR; Rantala, J; Risom, T; Sears, RC; Spellman, PT; Tomlin, CJ; Wang, NJ | 1 |
| Barbina, M; Bolis, M; Caponnetto, F; Damante, G; Di Loreto, C; Garattini, E; Gerratana, L; Mio, C; Puglisi, F; Zanello, A | 1 |
| Cahill, FF; Drobnitzky, N; Jiang, Y; Kong, A; Lourenco, LM; Mumin, NH; Patel, A; Ryan, AJ | 1 |
| Brothers, SP; Camarena, V; Huff, TC; Mustafi, S; Qureshi, R; Sant, DW; Slingerland, J; Volmar, CH; Wahlestedt, C; Wang, G; Yoon, H; Zheng, L | 1 |
| Boulware, D; Extermann, M; Goodridge, D; Han, HS; Hogue, D; Ismail-Khan, R; Khong, H; Shafique, M; Soliman, H; Sullivan, D | 1 |
| Angus, SP; Beltran, AS; Bevill, SM; Golitz, BT; Hale, A; Johnson, GL; Moorman, NJ; Olivares-Quintero, JF; Rashid, NU; Santos, CM; Sciaky, N; Singh, D; Stuhlmiller, TJ; Zawistowski, JS | 1 |
| Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Smith, DL; Zhang, C | 1 |
| Chrysikos, D; Dimopoulos, MA; Papadimitriou, CA; Psaltopoulou, T; Sergentanis, TN; Zagouri, F | 1 |
| Acquaviva, J; Bates, RC; El-Hariry, I; He, S; Jimenez, JP; Nagai, M; Proia, DA; Sang, J; Sequeira, M; Shapiro, GI; Smith, DL; Spector, N; Tolaney, S; Zhang, C | 1 |
| Chaturvedi, P; Gilkes, DM; Hu, H; Liang, H; Luo, W; Semenza, GL; Takano, N; Xiang, L | 1 |
| Fertig, EJ; Jin, K; Lee, E; Pandey, NB; Popel, AS; Sukumar, S | 1 |
| Bainer, R; Becker, L; Chada, K; Frankenberger, C; Gilad, Y; Krausz, T; Rabe, D; Rosner, MR; Sankarasharma, D | 1 |
| Bratta, M; Candeloro, G; D'Orazi, V; Fumagalli, LA; Pasta, V; Rea, S; Recchia, F; Rosselli, M | 1 |
| Settleman, J | 1 |
| Anders, L; Barry, WT; Bradner, JE; Brown, J; Brown, M; Carroll, JS; Chiang, CM; D'Santos, C; Dillon, D; Doherty, E; Duarte, M; Ekram, MB; Guo, H; He, HH; Huh, SJ; Janiszewska, M; Krop, IE; Letai, A; Liang, Y; Lin, CY; Liu, XS; Long, H; McKeown, M; Meyer, CA; Mohammed, H; Ni, M; Ott, C; Polyak, K; Qi, J; Rao, PK; Roberts, JM; Ryan, J; Shu, S; Stover, DG; Tabassum, DP; Winer, E; Witwicki, RM; Wu, SY; Young, RA | 1 |
| Agyeman, AS; Conzen, SD; Jun, WJ; Kim, CR; Kocherginsky, M; Proia, DA; Skor, MN | 1 |
| Corrales-Sánchez, V; Montero, JC; Ocaña, A; Pandiella, A; Pérez-Peña, J; Serrano-Heras, G | 1 |
| Chiu, HW; Ho, SY; Huang, WJ; Lin, P; Wang, YC; Wang, YJ; Yeh, YL | 1 |
| Baban, D; Bridges, E; da Motta, LL; De Bastiani, MA; Ebner, D; Haider, S; Harris, AL; Klamt, F; Knapp, S; Ledaki, I; Li, JL; McIntyre, A; Morotti, M; Purshouse, K; Steers, G; Wigfield, S | 1 |
| Angus, SP; Beltran, AS; Bevill, SM; Carey, LA; Chen, X; Darr, DB; Duncan, JS; Earp, HS; Gallagher, K; Golitz, BT; Goulet, DR; Graves, LM; He, X; Johnson, GL; Olivares-Quintero, JF; Parker, JS; Perou, CM; Rashid, NU; Santos, C; Sciaky, N; Singh, D; Stuhlmiller, TJ; Velarde, SH; Whittle, MC; Zawistowski, JS | 1 |
1 review(s) available for triazoles and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Hsp90 inhibitors in breast cancer: a systematic review.
Topics: Adenine; Antineoplastic Agents; Benzamides; Benzoquinones; Biomarkers, Tumor; Female; Glycine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Indazoles; Isoxazoles; Lactams, Macrocyclic; Pyridines; Resorcinols; Triazoles; Triple Negative Breast Neoplasms | 2013 |
2 trial(s) available for triazoles and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydrazines; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Rate; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Discoidin Domain Receptor 1; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Epigenesis, Genetic; Female; Heterocyclic Compounds, 4 or More Rings; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice, Inbred BALB C; Mice, SCID; Molecular Targeted Therapy; Nuclear Proteins; Positive Transcriptional Elongation Factor B; Pyridones; Pyrimidinones; RNA Interference; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
40 other study(ies) available for triazoles and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Design, synthesis and anti-TNBC activity of Azeliragon triazole analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Glycation End Products, Advanced; Humans; Imidazoles; Molecular Structure; Structure-Activity Relationship; Triazoles; Triple Negative Breast Neoplasms | 2021 |
Acute toxicity and antitumor potential of 1,3,4-trisubstituted-1,2,3-triazole dhmtAc-loaded liposomes on a triple-negative breast cancer model.
Topics: Animals; Cell Line, Tumor; Humans; Leukocytes, Mononuclear; Liposomes; Mice; Mice, Inbred BALB C; Structure-Activity Relationship; Triazoles; Triple Negative Breast Neoplasms | 2022 |
Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
Topics: Azepines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cysteine Endopeptidases; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Kisspeptins; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Scavenger Receptors, Class A; Sulfones; Triazoles; Triple Negative Breast Neoplasms | 2022 |
Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression.
Topics: Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Nuclear Proteins; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2022 |
LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mitosis; Nuclear Proteins; Paclitaxel; Protein Kinase Inhibitors; Triazoles; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Up-Regulation | 2020 |
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Dipeptides; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Proteolysis; Thalidomide; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2019 |
BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.
Topics: Azepines; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coculture Techniques; Female; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Programmed Cell Death 1 Receptor; Proteins; Signal Transduction; T-Lymphocytes; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azepines; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins; Receptors, Androgen; Signal Transduction; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.
Topics: Animals; Biological Availability; Cell Cycle; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chromosome Segregation; Chromosomes, Human; Drug Synergism; Humans; Mice; Paclitaxel; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrimidines; Spindle Apparatus; Triazoles; Triple Negative Breast Neoplasms | 2019 |
JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Topics: Animals; Antibodies; Apoptosis; Azepines; B7-H1 Antigen; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Indoles; Low-Level Light Therapy; Mice; Nanoparticles; Phototherapy; Polymers; Proto-Oncogene Proteins c-myc; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Lyases; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Naphthalenes; Nitriles; Phenylthiohydantoin; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Topics: Animals; Azepines; Biomarkers, Tumor; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Spheroids, Cellular; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice.
Topics: Animals; Apoptosis; Bone Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Doxorubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; RANK Ligand; Triazoles; Triple Negative Breast Neoplasms | 2020 |
BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Topics: Animals; Apoptosis; Azepines; B7-H1 Antigen; Biomarkers, Tumor; Cell Cycle Proteins; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Prognosis; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Checkpoints; Cell Proliferation; Clone Cells; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Mice; Models, Biological; Mutation; Paclitaxel; Piperazines; Ploidies; Proteins; Pyridines; Retinoblastoma Protein; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Nuclear Proteins; Proteins; Signal Transduction; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2020 |
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Female; Hedgehog Proteins; Humans; Mice, Inbred BALB C; Pyridines; Signal Transduction; Smoothened Receptor; Triazoles; Triple Negative Breast Neoplasms | 2020 |
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Mice, Inbred BALB C; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Pteridines; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Topics: Azepines; Bcl-2-Like Protein 11; Benzamides; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Survival; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Integrins; Proto-Oncogene Proteins c-myc; Pyrazines; RNA, Messenger; Signal Transduction; Sulfonamides; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2020 |
Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
Topics: Antibodies, Bispecific; Cell Line, Tumor; Female; Humans; Hydrazines; Triazoles; Triple Negative Breast Neoplasms | 2020 |
Apoptosis induction by 7-chloroquinoline-1,2,3-triazoyl carboxamides in triple negative breast cancer cells.
Topics: Apoptosis; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Triazoles; Triple Negative Breast Neoplasms | 2017 |
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Doxorubicin; Female; Furans; Humans; Hydrazines; Ketones; MCF-7 Cells; Mice; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Differential Expression and Pathway Analysis in Drug-Resistant Triple-Negative Breast Cancer Cell Lines Using RNASeq Analysis.
Topics: Antineoplastic Agents; Azepines; Cell Line, Tumor; Cytokines; Dexamethasone; Drug Resistance, Neoplasm; Humans; Receptors, Cytokine; Transcriptome; Triazoles; Triple Negative Breast Neoplasms | 2018 |
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.
Topics: Animals; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Plasticity; Chromatin; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Triazoles; Triple Negative Breast Neoplasms | 2018 |
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Topics: Antineoplastic Agents; Azepines; Benzodiazepines; BRCA1 Protein; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Humans; Nuclear Proteins; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Rad51 Recombinase; Recombinational DNA Repair; RNA Interference; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Interleukin-6; Janus Kinase 2; Signal Transduction; Small Molecule Libraries; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Ascorbic Acid; Azepines; Cell Line, Tumor; Dietary Supplements; Disease Models, Animal; Drug Synergism; Female; Gene Expression Profiling; Gene Silencing; Histone Deacetylase 1; Humans; Mice; Proteins; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Drug Synergism; Female; Humans; Indolizines; Nerve Tissue Proteins; Promoter Regions, Genetic; Receptors, Cell Surface; RNA Polymerase II; RNA, Ribosomal; Sulfones; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; HSP90 Heat-Shock Proteins; Humans; Inflammation; Mice, SCID; Molecular Targeted Therapy; Protein Stability; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mitosis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1; Immunoblotting; Immunohistochemistry; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neovascularization, Pathologic; Neural Cell Adhesion Molecule L1; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Triple Negative Breast Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis.
Topics: Aminosalicylic Acids; Animals; Antibodies, Neutralizing; Benzenesulfonates; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL5; Culture Media, Conditioned; Cyclohexanes; Female; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-6; Lung; Lymph Nodes; Lymphatic Metastasis; Lymphatic Vessels; Maraviroc; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Transplantation; STAT3 Transcription Factor; Transplantation, Heterologous; Triazoles; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2014 |
Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages.
Topics: Animals; Cell Line, Tumor; Chemokine CCL5; Chemokines; Chemotaxis; Cyclohexanes; Disease-Free Survival; Female; Gene Expression Profiling; Gene Knockdown Techniques; Heterografts; HMGA2 Protein; Humans; Macrophages; Mammary Neoplasms, Experimental; Maraviroc; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Phosphatidylethanolamine Binding Protein; Receptors, CCR5; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, RNA; Triazoles; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2015 |
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Endpoint Determination; Etoposide; Female; Humans; Ifosfamide; Immunotherapy; Interleukin-2; Isotretinoin; Leuprolide; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Triazoles; Triple Negative Breast Neoplasms | 2015 |
Cancer: Bet on drug resistance.
Topics: Animals; Azepines; Cell Cycle Proteins; Drug Resistance, Neoplasm; Female; Humans; Nuclear Proteins; Protein Structure, Tertiary; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2016 |
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Topics: Animals; Azepines; Binding, Competitive; Casein Kinase II; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chromatin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Mediator Complex Subunit 1; Mice; Nuclear Proteins; Phosphorylation; Phosphoserine; Protein Binding; Protein Phosphatase 2; Protein Structure, Tertiary; Proteomics; Transcription Factors; Transcription, Genetic; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Paclitaxel; Receptors, Glucocorticoid; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Computational Biology; Datasets as Topic; Disease Models, Animal; Drug Discovery; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Mice; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Topics: Animals; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Dioxoles; Down-Regulation; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Membrane Proteins; Mice; Proto-Oncogene Proteins; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
Topics: Animals; Azepines; Carbonic Anhydrase IX; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Female; Gene Expression Profiling; High-Throughput Nucleotide Sequencing; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Neovascularization, Pathologic; Promoter Regions, Genetic; Protein Binding; Spheroids, Cellular; Transcriptome; Triazoles; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |